Tumors defective for DNA polymerase (Pol) ε proofreading have the highest tumor mutation burden identified. A major unanswered question is whether loss of Pol ε proofreading by itself is sufficient to drive this mutagenesis, or whether additional factors are necessary. To address this, we used a combination of next generation sequencing and in vitro biochemistry on human cell lines engineered to have defects in Pol ε proofreading and mismatch repair. Absent mismatch repair, monoallelic Pol ε proofreading deficiency caused a rapid increase in a unique mutation signature, similar to that observed in tumors from patients with biallelic mismatch repair deficiency and heterozygous Pol ε mutations. Restoring mismatch repair was sufficient to suppress the explosive mutation accumulation. These results strongly suggest that concomitant suppression of mismatch repair, a hallmark of colorectal and other aggressive cancers, is a critical force for driving the explosive mutagenesis seen in tumors expressing exonuclease-deficient Pol ε.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829921 | PMC |
http://dx.doi.org/10.7554/eLife.32692 | DOI Listing |
Pediatr Blood Cancer
January 2025
Department of Oncology, Children's Hospital of Nanjing Medical University, Jiangsu, China.
Background: Compared to colorectal cancer (CRC) in adults, CRC in children is extremely rare. Although its incidence has increased recently, there is a lack of clinical research on the disease. Inherited cancer susceptibility syndromes (ICSS), a group of disorders in which patients are predisposed to susceptibility to a wide range of tumors as a result of pathogenic mutations in genes in their germ line, are an important cause of CRC in children.
View Article and Find Full Text PDFHistopathology
January 2025
Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.
Aims: We compiled two cohorts of colorectal adenosquamous carcinoma (ASC) to describe its histologic and molecular aspects using modern parameters to compare them with literature reports using meta-analysis of cohorts and individual case series.
Methods And Results: We identified 53 colorectal ASC from 19 North American academic medical centres, in addition to national database reports on 94 Dutch cases. We analysed available clinical, histologic, and immunohistochemical features and patient outcome.
Acta Oncol
January 2025
University of Iceland, Faculty of Medicine, Reykjavik, Iceland; Department of Oncology, Landspitali University Hospital of Iceland, Reykjavik, Iceland.
Background And Purpose: Screening for Lynch syndrome (LS) with mismatch repair (MMR) protein immunohistochemistry (IHC) in all patients with newly diagnosed colorectal (CRC) and endometrial cancer (EC) was implemented in Iceland in 2017. The aim of the study is to assess the accuracy of screening in 2020-2022 and compare it to 2017-2019 when screening was initiated.
Patients/materials And Methods: All patients diagnosed with CRC and EC according to the Icelandic Cancer Registry in 2020-2022 were included.
BMJ Oncol
April 2024
Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
BMJ Oncol
July 2024
Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Objective: To evaluate signal transducer and activator of transcription 3 (STAT3) inhibition we conducted a co-clinical trial testing danvatirsen, a STAT3 antisense oligonucleotide (ASO) and checkpoint inhibition in conjunction with preclinical experiments.
Methods And Analysis: Orthotopically implanted pancreatic cancer (pancreatic adenocarcinoma (PDAC)) was treated with STAT3 ASO with immune checkpoint inhibition. Tumour infiltrating immune cell populations were characterised via flow cytometry.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!